A Tucker man with Down syndrome is the only participant in a Vanderbilt clinical trial testing a potential treatment to lower ...
Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount of amyloid precursor protein (APP) for the potential treatment of Alzheimer ...
Elevated plasma p-tau217 signaled cognitive decline and dementia risk in people with Down syndrome. High p-tau217 and GFAP levels predicted future amyloid buildup. Down syndrome-related Alzheimer's ...
New research suggests a missing brain molecule may hold the key to understanding – and potentially treating – the faulty neural circuits seen in Down syndrome. Restoring the molecule, called ...
Experts explore the 2022 AAP Down syndrome health supervision guidelines and the SPIKES strategy for delivering compassionate, family-centered diagnoses.
Aelis Farma has launched its Phase IIb clinical trial evaluating AEF0217, targeting behavioural and cognitive impairments in ...
Brain lesions in Down syndrome aren’t always permanent. The vascular changes can fluctuate or even decrease over time as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results